NCT06194461Not yet recruiting
LTFU for All Cell and Gene Therapy Studies
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 64 (estimated)
- First submitted
- 7 Dec 2023
- Start date
- 17 Sept 2025
- Primary completion date
- 29 Nov 2041
- Lead sponsor
- AstraZeneca
- NCT number
- NCT06194461
What you commit to
- Study type: Observational
- Planned participants: 64
- From 17 Sept 2025 to the primary completion date, 29 Nov 2041
- 23 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable
- \-
Who the study is looking for
- The participant has received a cell or gene therapy in another AstraZeneca protocol.
- Provision of signed and dated, written informed consent before any study-specific procedures.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (23)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.